Glaukos Corporation (GKOS)

106.51 +1.48 (+1.41%) 收市：04:00PM EDT

Glaukos Corporation

One Glaukos Way
Aliso Viejo, CA 92656
United States
949 367 9600
https://www.glaukos.com

版塊: Healthcare
行業: Medical Devices
全職員工: 907

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Thomas William Burns	Chairman & CEO	774.9k	24.98M	1961
Mr. Joseph E. Gilliam	President & COO	1.18M	4.01M	1976
Mr. Alex R. Thurman	Senior VP & CFO	621.24k	無	1970
Dr. Tomas Navratil Ph.D.	Chief Development Officer	866.18k	無	1977
Dr. Mory Gharib Ph.D.	Co-Founder	無	無	無
Mr. Christopher William Lewis	Vice President of Investor Relations & Corporate Affairs	無	無	無
Ms. Diana A. Scherer	VP of Compliance & Deputy General Counsel	無	無	無
Ms. Michele M. Allegretto	Senior Vice President of Human Resources	無	無	無
Mr. Chris M. Calcaterra	Executive Vice President of Global Commercial Operations	198.66k	無	1960
Ms. Jane E. Rady	Senior Vice President of Corporate Strategy & Business Development	無	無	1948

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

公司管治

截至 2024年5月1日 止，Glaukos Corporation 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：1；董事會：7；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。